Valganciclovir Treatment in a 6-month-old Infant With Asymptomatic Congenital Cytomegalovirus Infection and Late Hearing Loss

Stronati, Mauro; Garofoli, Francesca; Angelini, Micol; Licari, Amelia; Manzoni, Paolo; Lombardi, G

doi:10.1097/inf.0b013e3182293439

Cited by 6 publications

(8 citation statements)

References 15 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isolated cases of successful treatment of CMV-related late-onset hearing deterioration have been previously reported. 12,13 Our infants showed more improvement than reported in infants born with symptomatic congenital CMV infection and hearing loss treated during the neonatal period. 6,7 This unexpected result may be explained by the poorer general health of the symptomatic infants who had more severe intrauterine infections and presented with signs and symptoms in various organs at birth.…”

Section: Discussionmentioning

confidence: 60%

See 1 more Smart Citation

Treatment of Late-Onset Hearing Loss in Infants With Congenital Cytomegalovirus Infection

Amir

Attias

Pardo

2013

Clin Pediatr (Phila)

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 60%

“…Fluctuating hearing loss, predominantly in the first year of life, has also been reported in infants with congenital CMV infection. 3,13,16 One study found that the events were few in number, with hearing close to the normal threshold. 16 Others showed that in most cases, hearing deteriorated on follow-up.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Late-Onset Hearing Loss in Infants With Congenital Cytomegalovirus Infection

Amir

Attias

Pardo

2013

Clin Pediatr (Phila)

View full text Add to dashboard Cite

show abstract

“…Of the 24 articles, four were RCTs, two were randomised cluster control trials, three were non‐randomised phase I/II trials, six were observational studies, three were case–control studies and six were case series (Table ). Thirty‐seven case reports were also identified and not included in this review but were detailed elsewhere (Supplementary Table ).…”

Section: Resultsmentioning

confidence: 99%

Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review

et al. 2014

View full text Add to dashboard Cite

Human cytomegalovirus is the leading non-genetic cause of congenital malformation in developed countries. Congenital CMV may result in fetal and neonatal death or development of serious clinical sequelae. In this review, we identified evidence-based interventions for prevention of congenital CMV at the primary level (prevention of maternal infection), secondary level (risk reduction of fetal infection and disease) and tertiary level (risk reduction of infected neonates being affected by CMV). A systematic review of existing literature revealed 24 eligible studies that met the inclusion criteria. Prevention of maternal infection using hygiene and behavioural interventions reduced maternal seroconversion rates during pregnancy. However, evidence suggested maternal adherence to education on preventative behaviours was a limiting factor. Treatment of maternal CMV infection with hyperimmune globulin (HIG) showed some evidence for efficacy in prevention of fetal infection and fetal/neonatal morbidity with a reasonable safety profile. However, more robust clinical evidence is required before HIG therapy can be routinely recommended. Limited evidence also existed for the safety and efficacy of established CMV antivirals (valaciclovir, ganciclovir and valganciclovir) to treat neonatal consequences of CMV infection, but toxicity and lack of randomised clinical trial data remain major issues. In the absence of a licensed CMV vaccine or robust clinical evidence for anti-CMV therapeutics, patient education and behavioural interventions that emphasise adherence remain the best preventative strategies for congenital CMV. There is a strong need for further data on the use of HIG and other antivirals in pregnancy, as well as the development of less toxic, novel, antiviral agents.

show abstract

“…All included studies reported the clinical characteristics of children with cCMV, except for the study by Stronati et al [29].…”

Section: Clinical Features (Table 2)mentioning

confidence: 99%

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Background: Cytomegalovirus (CMV) is the most common agent of congenital infection in humans. It is a main cause of neurodevelopmental delay and sensorineural hearing loss in infancy. Since the 2000s, a number of studies have used Valganciclovir as a therapy for children with congenital CMV infection. Methods: In order to evaluate the efficacy of Valganciclovir in preventing clinical sequelae and its possible side effects, we performed a review of the published literature. This search was completed via PubMed for manuscripts published from January 2007 to December 2021, combining the MeSH words “Valganciclovir”, “Congenital”, and “Cytomegalovirus”. Results: A total of 27 articles were included (12 retrospective studies, 4 prospective studies, 1 randomized controlled trial, and 10 case reports). The clinical features were similar to those already described in the literature. The therapeutic protocols used were very different between the various studies included and neonatal antiviral treatments were only moderately effective. The therapy proved to be well-tolerated. Conclusions: The quality of the included studies and the sample size were limited due to the rarity of the disease. The use of different therapeutic protocols in terms of starting dates, doses, and durations made it impossible to compare and correctly evaluate the efficacy of the treatments. Randomized controlled trials are needed to establish the correct effective dose with the fewest side effects and the most efficient duration of therapy.

show abstract

Valganciclovir Treatment in a 6-month-old Infant With Asymptomatic Congenital Cytomegalovirus Infection and Late Hearing Loss

Cited by 6 publications

References 15 publications

Treatment of Late-Onset Hearing Loss in Infants With Congenital Cytomegalovirus Infection

Treatment of Late-Onset Hearing Loss in Infants With Congenital Cytomegalovirus Infection

Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature

Contact Info

Product

Resources

About